Status:
UNKNOWN
A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control
Lead Sponsor:
University Health Network, Toronto
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Albuterol (salbutamol) is a widely used asthma medication but is associated with undesirable side effects such as shakiness and increased heart rate. Targeted delivery of albuterol to area of lungs wh...
Detailed Description
Side effects of albuterol (salbutamol)are directly related to the dose delivered and absorbed into blood stream. By controlling aerosol delivery, dose delivered, site of deposition, amount of drug abs...
Eligibility Criteria
Inclusion
- Male or female aged 18-60 years
- Moderate asthma with baseline FEV1 40-75% predicted
- Previous use of albuterol (salbutamol)
- At least 20% improvement in FEV1 following 2.5 mg albuterol (salbutamol) delivered by nebulizer
- O2 saturation \> 90%
- Non-smoker for \> 6 months
Exclusion
- Upper respiratory tract infection or asthma exacerbation within 14 days of screening
- Clinically significant abnormal chest radiograph
- History of cardiovascular disorder including coronary insufficiency, cardiac arrhythmias or hypertension
- Unable to tolerate bronchodilator withdrawal
- Known hypersensitivity to albuterol (salbutamol)
- Change in asthma treatment regimen in past 30 days
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00385359
Start Date
October 1 2006
Last Update
October 9 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto Western Hospital - Respiratory Research Lab
Toronto, Ontario, Canada, M5T 2S8